CRSTI
7777 Forest Lane
Suite C-742
Dallas, TX 75230
972-566-6820
fax: 972-566-8524
info@crsti.org
Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF)
Sponsor: National Institute of Health
Investigator: Allan Anderson, MD
Research Coordinator: Tonya Goldston, RN, BSN, CCRC
Designated Site: Medical City Dallas
The primary aim of this trial is to determine whether warfarin (International Normalized Ratio [INR] 2.5-3.0, target INR 2.75) or aspirin (325 mg per day) is superior for preventing all-cause mortality and stroke combined in patients with ejection fraction (EF) =35%, when balanced against any risk of intracerebral hemorrhage.